avid bioservices, a subsidiary of peregrine pharmaceuticals, inc. (nasdaq: pphm), is a unique contract manufacturing organization ("cmo") partner dedicated to the development and production of monoclonal antibodies, recombinant proteins and enzymes produced in mammalian cell culture. our extensive experience at all stages of development enables us to provide comprehensive development, manufacturing and support services to navigate a biologic from concept to commercialization.
Company profile
Ticker
CDMO
Exchange
Website
CEO
Richard Hancock
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PEREGRINE PHARMACEUTICALS INC, TECHNICLONE CORP/DE/, TECHNICLONE INTERNATIONAL CORP
SEC CIK
Corporate docs
IRS number
953698422
CDMO stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
NT 10-Q
Notice of late quarterly filing
12 Mar 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
12 Mar 24
8-K
Results of Operations and Financial Condition
7 Mar 24
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
6 Mar 24
10-Q
2024 Q2
Quarterly report
7 Dec 23
8-K
Results of Operations and Financial Condition
7 Dec 23
8-K
Corporate Presentation December 2023
6 Dec 23
8-K/A
Submission of Matters to a Vote of Security Holders
17 Nov 23
Transcripts
CDMO
Earnings call transcript
2024 Q2
7 Dec 23
CDMO
Earnings call transcript
2024 Q1
7 Sep 23
CDMO
Earnings call transcript
2023 Q4
21 Jun 23
CDMO
Earnings call transcript
2023 Q3
13 Mar 23
CDMO
Earnings call transcript
2023 Q2
7 Dec 22
CDMO
Earnings call transcript
2023 Q1
7 Sep 22
CDMO
Earnings call transcript
2022 Q4
30 Jun 22
CDMO
Earnings call transcript
2022 Q3
9 Mar 22
CDMO
Earnings call transcript
2022 Q2
7 Dec 21
CDMO
Earnings call transcript
2022 Q1
9 Sep 21
Latest ownership filings
SC 13G
T. Rowe Price Investment Management, Inc.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
AltraVue Capital, LLC
26 Jan 24
SC 13G/A
STATE STREET CORP
25 Jan 24
4
Matthew R. Kwietniak
12 Jan 24
4
Mark R Ziebell
11 Jan 24
4
Richard A. Richieri
11 Jan 24
4
Matthew R. Kwietniak
11 Jan 24
4
Daniel R Hart
11 Jan 24
4
Nicholas Stewart Green
11 Jan 24
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Apr 23 | Apr 22 | Apr 21 | Apr 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 31.42 mm | 31.42 mm | 31.42 mm | 31.42 mm | 31.42 mm | 31.42 mm |
Cash burn (monthly) | (no burn) | 3.85 mm | 3.96 mm | 918.08 k | (no burn) | (no burn) |
Cash used (since last report) | n/a | 19.06 mm | 19.61 mm | 4.54 mm | n/a | n/a |
Cash remaining | n/a | 12.36 mm | 11.82 mm | 26.88 mm | n/a | n/a |
Runway (months of cash) | n/a | 3.2 | 3.0 | 29.3 | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 172 |
Opened positions | 20 |
Closed positions | 21 |
Increased positions | 52 |
Reduced positions | 69 |
13F shares | Current |
---|---|
Total value | 553.24 bn |
Total shares | 65.80 mm |
Total puts | 4.80 k |
Total calls | 5.90 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 9.67 mm | $91.31 bn |
Vanguard | 4.43 mm | $41.79 bn |
T. Rowe Price Investment Management | 4.10 mm | $38.70 bn |
STT State Street | 3.74 mm | $35.26 bn |
AltraVue Capital | 3.01 mm | $28.41 bn |
Iszo Capital | 2.38 mm | $27.43 mm |
Ranger Investment Management | 2.28 mm | $21.53 bn |
Jennison Associates | 2.27 mm | $21.44 bn |
Snyder Capital Management L P | 2.23 mm | $21.06 bn |
Tappan Street Partners | 2.18 mm | $64.66 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Jan 24 | Matthew R. Kwietniak | Common Stock, $0.001 par value | Sell | Dispose S | No | No | 6.77 | 274 | 1.85 k | 19,829 |
11 Jan 24 | Matthew R. Kwietniak | Common Stock, $0.001 par value | Option exercise | Acquire M | No | No | 0 | 669 | 0.00 | 20,103 |
11 Jan 24 | Matthew R. Kwietniak | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 669 | 0.00 | 35,097 |
10 Jan 24 | Richard A. Richieri | Common Stock, $0.001 par value | Sell | Dispose S | Yes | No | 6.17 | 116 | 715.72 | 5,208 |
10 Jan 24 | Richard A. Richieri | Common Stock, $0.001 par value | Sell | Dispose S | No | No | 6.17 | 1,055 | 6.51 k | 25,625 |
10 Jan 24 | Matthew R. Kwietniak | Common Stock, $0.001 par value | Sell | Dispose S | No | No | 6.1698 | 1,060 | 6.54 k | 19,434 |
10 Jan 24 | Ziebell Mark R | Common Stock, $0.001 par value | Sell | Dispose S | No | No | 6.17 | 1,346 | 8.30 k | 63,269 |
10 Jan 24 | Hart Daniel Ryan | Common Stock, $0.001 par value | Sell | Dispose S | No | No | 6.1697 | 2,408 | 14.86 k | 79,305 |
9 Jan 24 | Richard A. Richieri | Common Stock, $0.001 par value | Option exercise | Acquire M | Yes | No | 0 | 132 | 0.00 | 5,324 |
9 Jan 24 | Richard A. Richieri | Common Stock, $0.001 par value | Option exercise | Acquire M | Yes | No | 0 | 83 | 0.00 | 5,192 |
News
Stephens & Co. Maintains Overweight on Avid Bioservices, Lowers Price Target to $12
11 Mar 24
9 Health Care Stocks Whale Activity In Today's Session
8 Mar 24
S&P 500 Gains 1%; Kroger Earnings Top Views
7 Mar 24
Biotech/Pharma Contract Service Provider Avid Bioservices Sees Lower Than Expected Q3 Sales, Sticks To Annual Guidance
7 Mar 24
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
7 Mar 24
Press releases
Avid Bioservices (CDMO) Falls Further After Disclosing Intent to Restate Financial Statements Due to Misclassification of $146 Million of 2026 Notes as Long-Term Liabilities – Hagens Berman
28 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
27 Mar 24
CDMO LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avid Bioservices, Inc. Investors to Inquire About Securities Class Action Investigation – CDMO
23 Mar 24
Avid Bioservices (CDMO) Falls Further After Disclosing Intent to Restate Financial Statements Due to Misclassification of $146 Million of 2026 Notes as Long-Term Liabilities – Hagens Berman
21 Mar 24
SHAREHOLDER ALERT: Avid Bioservices Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
20 Mar 24